Alvotech (ALVO) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Alvotech announces the European Medicines Agency’s acceptance of their Marketing Authorization Application for AVT03, a biosimilar candidate to osteoporosis treatments Prolia and Xgeva. This step is significant for expanding patient access in Europe to cost-effective biologic medicines. The European denosumab market, which AVT03 aims to enter, is currently valued at approximately US$1 billion.
For further insights into ALVO stock, check out TipRanks’ Stock Analysis page.
